DK2285786T3 - Quinoxalindion-derivater - Google Patents

Quinoxalindion-derivater

Info

Publication number
DK2285786T3
DK2285786T3 DK09765489.1T DK09765489T DK2285786T3 DK 2285786 T3 DK2285786 T3 DK 2285786T3 DK 09765489 T DK09765489 T DK 09765489T DK 2285786 T3 DK2285786 T3 DK 2285786T3
Authority
DK
Denmark
Prior art keywords
quinoxalinedione derivatives
quinoxalinedione
derivatives
Prior art date
Application number
DK09765489.1T
Other languages
English (en)
Inventor
Daniel Cravo
Sophie Hallakou-Bozec
Franck Lepifre
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK2285786T3 publication Critical patent/DK2285786T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK09765489.1T 2008-06-16 2009-05-19 Quinoxalindion-derivater DK2285786T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290564 2008-06-16
PCT/EP2009/003538 WO2009152909A1 (en) 2008-06-16 2009-05-19 Quinoxalinedione derivatives

Publications (1)

Publication Number Publication Date
DK2285786T3 true DK2285786T3 (da) 2013-11-04

Family

ID=40823394

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09765489.1T DK2285786T3 (da) 2008-06-16 2009-05-19 Quinoxalindion-derivater

Country Status (25)

Country Link
US (2) US8329698B2 (da)
EP (1) EP2285786B1 (da)
JP (1) JP5596676B2 (da)
KR (1) KR101641391B1 (da)
CN (1) CN102066342B (da)
AR (1) AR072148A1 (da)
AU (1) AU2009259754B2 (da)
BR (1) BRPI0915064B8 (da)
CA (1) CA2728018C (da)
CO (1) CO6321252A2 (da)
CY (1) CY1114737T1 (da)
DK (1) DK2285786T3 (da)
EA (1) EA020236B1 (da)
EC (1) ECSP11010760A (da)
ES (1) ES2436195T3 (da)
HK (1) HK1157784A1 (da)
HR (1) HRP20131069T1 (da)
IL (1) IL209421A (da)
MX (1) MX2010013577A (da)
MY (1) MY155695A (da)
NZ (1) NZ590503A (da)
PL (1) PL2285786T3 (da)
PT (1) PT2285786E (da)
SI (1) SI2285786T1 (da)
WO (1) WO2009152909A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
BR112014026703B1 (pt) 2012-04-24 2022-10-25 Vertex Pharmaceuticals Incorporated Inibidores de dna-pk e seus usos, composição farmacêutica e seus usos, e método de sensibilização de uma célula
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
EP3424920B1 (en) 2013-10-17 2020-04-15 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna損傷剤とdna−pk阻害剤との組合せ物を使用する、がんを処置するための方法
EP3941496A4 (en) * 2019-03-18 2022-11-23 University of Washington METHOD OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS
CN110642798B (zh) * 2019-11-10 2020-07-24 湖南科技学院 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
WO2022072397A1 (en) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
US20240067645A1 (en) * 2020-11-26 2024-02-29 Lg Chem, Ltd. Heterocyclic compound as diacylglycerol kinase inhibitor and use thereof
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
CA2278757A1 (en) 1997-02-18 1998-08-20 Uresh Shantilal Shah 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
EP1397134A2 (en) 2001-05-25 2004-03-17 Boehringer Ingelheim Pharma GmbH & Co.KG Combination of a dopamine d2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways
CN1901917A (zh) 2004-01-06 2007-01-24 詹森药业有限公司 作为糖原磷酸化酶抑制剂用于治疗糖尿病和肥胖症的(3-氧代-3,4-二氢-喹喔啉-2-基-氨基)-苯甲酰胺衍生物和相关化合物
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US20090312321A1 (en) * 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PT2285786E (pt) 2014-01-07
EA201100007A1 (ru) 2011-08-30
AU2009259754B2 (en) 2014-10-02
WO2009152909A1 (en) 2009-12-23
CA2728018A1 (en) 2009-12-23
SI2285786T1 (sl) 2014-02-28
CY1114737T1 (el) 2016-12-14
ECSP11010760A (es) 2011-02-28
ES2436195T3 (es) 2013-12-27
PL2285786T3 (pl) 2014-01-31
CO6321252A2 (es) 2011-09-20
AR072148A1 (es) 2010-08-11
KR101641391B1 (ko) 2016-07-20
BRPI0915064A2 (pt) 2015-10-27
US8329698B2 (en) 2012-12-11
US20120322806A1 (en) 2012-12-20
JP5596676B2 (ja) 2014-09-24
EA020236B1 (ru) 2014-09-30
EP2285786A1 (en) 2011-02-23
IL209421A (en) 2015-06-30
US20110130404A1 (en) 2011-06-02
IL209421A0 (en) 2011-01-31
MY155695A (en) 2015-11-13
BRPI0915064B8 (pt) 2021-05-25
BRPI0915064B1 (pt) 2019-10-08
HK1157784A1 (en) 2012-07-06
CA2728018C (en) 2016-10-11
EP2285786B1 (en) 2013-10-09
KR20110017455A (ko) 2011-02-21
JP2011524384A (ja) 2011-09-01
US8674097B2 (en) 2014-03-18
CN102066342B (zh) 2013-09-04
MX2010013577A (es) 2010-12-21
HRP20131069T1 (hr) 2013-12-20
AU2009259754A1 (en) 2009-12-23
CN102066342A (zh) 2011-05-18
NZ590503A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
DK2285786T3 (da) Quinoxalindion-derivater
DK2308877T3 (da) Imidazopyridin-2-on-derivater
BRPI0907376A2 (pt) Fotobiorretador
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
BRPI0914649A2 (pt) Piprazolo-quinazolinas
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
DK2342454T3 (da) Vindkraftanlæg
DK2275414T3 (da) Cyclopentylacrylamidderivat
DE602008003970D1 (de) Strahlstromkalibriersystem
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
DK2190837T3 (da) 4-pyrimidinsulfamid-derivat
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI0907522A2 (pt) biarlamidas
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
BRPI0922652A2 (pt) Derivados de quinazolinamida
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0909634A2 (pt) 2-aminoquinolinas